Enzyme replacement therapy in mucopolysaccharidosis type I: progress and emerging difficulties

Area of Science:

• Biochemistry
• Genetics
• Lysosomal Storage Disorders

Background:

• Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disorder caused by alpha-L-iduronidase deficiency.
• This deficiency impairs the breakdown of heparan and dermatan sulfate glycosaminoglycans.
• MPS I presents a spectrum of phenotypes, from severe (Hurler) to mild (Scheie), impacting lifespan and quality of life.

Purpose of the Study:

• To review the progress in enzyme replacement therapy (ERT) for Mucopolysaccharidosis type I.
• To discuss the utility of a naturally occurring canine model in understanding MPS I and developing therapies.
• To highlight potential challenges associated with the implementation of ERT for MPS I.

Main Methods:

• Literature review of enzyme replacement therapy development for MPS I.
• Analysis of a canine model exhibiting MPS I-like phenotypes.
• Discussion of clinical manifestations and therapeutic outcomes in MPS I patients.

Main Results:

• Enzyme replacement therapy has been developed as a potential treatment for MPS I.
• A canine model closely mimics the Hurler/Scheie (MPS IH/S) phenotype, aiding therapeutic research.
• The study identifies both advancements and potential obstacles in introducing ERT for MPS I.

Conclusions:

• Enzyme replacement therapy offers a promising therapeutic avenue for MPS I patients.
• Canine models are valuable tools for studying MPS I and evaluating treatment efficacy.
• Careful consideration of challenges is crucial for the successful clinical introduction of ERT for MPS I.